BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) COO Xiaobin Wu sold 578 shares of BeiGene stock in a transaction on Friday, June 17th. The stock was sold at an average price of $139.60, for a total value of $80,688.80. Following the sale, the chief operating officer now owns 1,010 shares of the company’s stock, valued at $140,996. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Xiaobin Wu also recently made the following trade(s):
- On Tuesday, June 21st, Xiaobin Wu sold 1,010 shares of BeiGene stock. The stock was sold at an average price of $144.36, for a total value of $145,803.60.
- On Monday, June 6th, Xiaobin Wu sold 3,410 shares of BeiGene stock. The stock was sold at an average price of $141.99, for a total value of $484,185.90.
- On Thursday, May 5th, Xiaobin Wu sold 6,725 shares of BeiGene stock. The stock was sold at an average price of $164.35, for a total value of $1,105,253.75.
BGNE opened at $156.20 on Friday. The business’s 50-day moving average is $146.75 and its two-hundred day moving average is $198.32. BeiGene, Ltd. has a 1 year low of $118.18 and a 1 year high of $426.56. The company has a current ratio of 5.05, a quick ratio of 4.87 and a debt-to-equity ratio of 0.03.
Several analysts recently weighed in on the company. Morgan Stanley lifted their price objective on BeiGene from $330.00 to $338.00 and gave the company an “overweight” rating in a report on Tuesday, April 12th. SVB Leerink downgraded BeiGene from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $300.00 to $177.00 in a report on Thursday, March 17th. Finally, StockNews.com downgraded BeiGene from a “hold” rating to a “sell” rating in a report on Thursday, June 16th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, BeiGene currently has an average rating of “Moderate Buy” and a consensus target price of $315.33.
Several hedge funds have recently modified their holdings of the company. Bank of America Corp DE grew its stake in shares of BeiGene by 77.1% during the first quarter. Bank of America Corp DE now owns 414,466 shares of the company’s stock worth $78,169,000 after acquiring an additional 180,470 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of BeiGene by 155.4% during the first quarter. The Manufacturers Life Insurance Company now owns 20,175 shares of the company’s stock worth $4,010,000 after acquiring an additional 12,275 shares during the last quarter. Capital International Sarl grew its stake in shares of BeiGene by 38.3% during the first quarter. Capital International Sarl now owns 172,972 shares of the company’s stock worth $32,623,000 after acquiring an additional 47,918 shares during the last quarter. Capital Group International Inc. CA grew its stake in shares of BeiGene by 14.1% during the first quarter. Capital Group International Inc. CA now owns 1,140,960 shares of the company’s stock worth $215,185,000 after acquiring an additional 141,133 shares during the last quarter. Finally, Capital International Investors boosted its position in BeiGene by 11.2% in the first quarter. Capital International Investors now owns 7,055,295 shares of the company’s stock valued at $1,337,378,000 after buying an additional 711,396 shares during the last quarter.
About BeiGene (Get Rating)
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).
- Get a free copy of the StockNews.com research report on BeiGene (BGNE)
- Ciena Stock Giving Window of Opportunity
- Zai Lab Stock Has Fallen to Value Levels
- Are These Cheap Copper Stocks Right For Your Portfolio?
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.